Sunshine Biopharma (SBFM) grants director Natan David 58,300 common shares

Rhea-AI Filing Summary

NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.

Sunshine Biopharma Inc. director Natan David received a stock award of 58,300 shares of common stock on August 7, 2026. The award was granted at a stated price of $0.00 per share and increased his directly held position to 68,300 common shares following the transaction. A footnote clarifies that this represents a stock award to the reporting person.

Insider Trade Summary

Net Buyer: 58,300 shares

Net Buy 1 txn

Insider NATAN DAVID

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	58,300	$0.00	$0.00

Holdings After Transaction: Common Stock — 68,300 shares (Direct)

Footnotes (1)

1. F1. Represents a stock award to the reporting person.

Key Figures

Shares awarded: 58,300 shares of common stock Price per share: $0.00 per share Holdings after transaction: 68,300 shares +1 more

4 metrics

Shares awarded 58,300 shares of common stock Stock award to director Natan David on August 7, 2026

Price per share $0.00 per share Stated transaction price for the 58,300-share stock award

Holdings after transaction 68,300 shares Direct common stock holdings of Natan David following the award

Transactions reported 1 grant/award acquisition Single non-derivative Form 4 transaction coded as A (Grant, award, or other acquisition)

Key Terms

stock award, grant, award, or other acquisition, Form 4

3 terms

stock award financial

"Represents a <b>stock award</b> to the reporting person."

grant, award, or other acquisition financial

"Transaction code A is described as <b>Grant, award, or other acquisition</b>."

Form 4 regulatory

"Insider transaction is disclosed on SEC <b>Form 4</b> for Natan David."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did Sunshine Biopharma (SBFM) report for Natan David?

Sunshine Biopharma reported that director Natan David received a stock award of 58,300 common shares on August 7, 2026, classified as a grant or award acquisition with no cash purchase price stated.

How many Sunshine Biopharma (SBFM) shares were granted to Natan David?

Natan David was granted 58,300 shares of Sunshine Biopharma common stock. The transaction is coded as a grant or award, and a footnote states it represents a stock award to the reporting person.

What is Natan David’s total Sunshine Biopharma (SBFM) holding after this Form 4 transaction?

After the reported stock award, Natan David directly holds 68,300 shares of Sunshine Biopharma common stock. This figure reflects his position immediately following the August 7, 2026 award transaction.

Was cash paid for the Sunshine Biopharma (SBFM) shares awarded to Natan David?

The award shows a transaction price of $0.00 per share, indicating no cash purchase price for the 58,300 shares. A footnote identifies the transaction as a stock award to the reporting person.

Is the Sunshine Biopharma (SBFM) Form 4 transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirming a plan. The transaction is reported simply as a stock award, with no indication that it was executed under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:23 PM Accepted by SEC EDGAR 08/11/2026 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NATAN DAVID

(Last) (First) (Middle)

C/O SUNSHINE BIOPHARMA, INC.

333 LA OLAS WAY, CU SUITE 433

(Street)

FORT LAUDERDALE FLORIDA 33301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sunshine Biopharma Inc. [ SBFM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2026		A(1)		58,300	A	$0	68,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a stock award to the reporting person.

	/s/ David Natan	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)